AQST Class Action Notice: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Aquestive Therapeutics, Inc. Class Action Lawsuit

Core Viewpoint - A class action has been filed against Aquestive Therapeutics, Inc. for allegedly misleading investors regarding the approval status of its drug Anaphylm, leading to a significant decline in stock price after the announcement of deficiencies by the FDA [1][2][3]. Allegations - The complaint alleges that during the class period, Aquestive created a false impression that it was on track to receive approval for Anaphylm by the January 31, 2026 PDUFA date, while the FDA had identified deficiencies that precluded further discussions [2]. - On January 9, 2026, Aquestive disclosed that it received a letter from the FDA indicating ongoing review and deficiencies, which delayed the approval process beyond the expected date [3]. Stock Impact - Following the announcement of the FDA's findings, Aquestive's stock price fell over 37%, dropping from $6.21 per share on January 8, 2026, to $3.91 per share on January 9, 2026 [3]. Class Action Participation - Shareholders interested in participating as lead plaintiffs must submit their papers by May 4, 2026, but they can also choose to remain absent class members without participating in the case [4]. Legal Representation - Robbins LLP operates on a contingency fee basis, meaning shareholders incur no fees or expenses unless the case is won [5].